Trial Profile
A Phase I , Open-Label Study to Evaluate the Absorption, Metabolism and Excretion of [14C]-PBT2 and to Estimate the Absolute Bioavailability of PBT2 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2019
Price :
$35
*
At a glance
- Drugs PBT 2 (Primary) ; PBT 2 (Primary)
- Indications Alzheimer's disease; Huntington's disease
- Focus Pharmacokinetics
- Sponsors Alterity Therapeutics
- 10 Apr 2019 According to an Alterity Therapeutics Limited media release, the company was formerly called as Prana Biotechnology Limited.
- 29 Sep 2014 New trial record